GridAI Technologies Corp.
GRDX evidence brief
What we can confirm
- BioSniper Score:
- 6.4 / 10
- Market Cap:
- $20.4M
- Lead Asset:
- adrulipase (Phase 2)
What it means
What to watch
Prepared research question
What matters most for GRDX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GRDX
GridAI Technologies Corp. (GRDX) is a post-acquisition entity combining AI-driven energy optimization technology with legacy biopharmaceutical development, primarily focused on the Adrulipase program for exocrine pancreatic insufficiency.
Key risk: Insufficient cash for Phase 3
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$20.4M
Cash Runway
—
Lead Asset
adrulipase (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for GridAI Technologies Corp..
GridAI Technologies Corp. (GRDX) is a post-acquisition entity combining AI-driven energy optimization technology with legacy biopharmaceutical development, primarily focused on the Adrulipase program for exocrine pancreatic insufficiency.
- Following the acquisition of Grid AI Corp., the company now operates both an AI-driven energy technology business and a legacy biopharmaceutical development business [sec · filed 2026-09-18].
- The Grid AI business focuses on AI-driven energy optimization, distributed energy resource management, battery storage, and energy orchestration [sec_mda · as of 2026-09-18].
- The legacy biopharmaceutical activities are centered on Adrulipase, an oral, non-systemic biologic capsule for exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis [sec_mda · as of 2025-08-14].
- As of 2026-06-30, the company reported cash & equivalents of $1.4M and total revenue of $0.1M [sec].
- The company plans to continue development of Adrulipase, including preparation for a Phase 3 clinical trial, subject to additional capital [sec · filed 2026-07-31].
What works
- The company has a diversified technology portfolio spanning AI-driven energy optimization and biopharmaceuticals, which may provide multiple revenue pathways [sec_mda · as of 2026-09-18].
- The Adrulipase program targets large patient populations (cystic fibrosis and chronic pancreatitis) and, according to the Board, has clearer regulatory pathways compared to other assets [sec · filed 2025-09-10].
- The company has secured private placements in May and July 2026, which management believes will fund operations (excluding Phase 3 for Adrulipase) for at least 18 months [sec · filed 2026-07-31].
What to weigh
- The company has very limited revenue ($0.1M as of 2026-06-30) and low cash reserves ($1.4M as of 2026-06-30), indicating a high dependency on external financing [sec].
- Commencement of the planned Phase 3 clinical trial for Adrulipase will require additional capital beyond current resources [sec · filed 2026-07-31].
- Several prior transactions (reverse merger with Journey Therapeutics, license with Data Vault, sale of Niclosamide program) are not expected to move forward, suggesting challenges in executing strategic deals [sec_mda · as of 2025-08-14].
- The company's financial condition has previously raised substantial doubt about its ability to continue as a going concern [sec_mda · as of 2025-04-01].
From the filings
Quoted directly from source documents.
The company's business includes both AI-driven energy technology and legacy biopharmaceutical activities.
“Following the acquisition of Grid AI Corp., our business includes both AI-driven energy technology activities and legacy biopharmaceutical development activities.”
SEC filings · September 18, 2026
Adrulipase is an oral, non-systemic biologic capsule for exocrine pancreatic insufficiency.
“Our Adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency (" EPI ") in patients with cystic fibrosis (" CF ") and chronic pancreatitis (" CP ").”
SEC MD&A · August 14, 2025
The Phase 3 trial for Adrulipase requires additional capital.
“will be sufficient to fund these activities -- including platform development, operating expenses, integration costs and personnel -- and its operations, other than the commencement of the planned Phase 3 clinical trial for Adrulipase (which will require additional capital), for at least the next 18 months from the date of th”
SEC filings · July 31, 2026
The company's financial condition has raised substantial doubt about its ability to continue as a going concern.
“Our current financial condition raises substantial doubt about our ability to continue as a going concern.”
SEC MD&A · April 1, 2025
Risks & what to watch (4)›
Key risks
- Insufficient cash for Phase 3 — The planned Phase 3 trial for Adrulipase requires additional capital beyond current resources [sec · filed 2026-07-31].
- Going concern uncertainty — The company's financial condition has previously raised substantial doubt about its ability to continue as a going concern [sec_mda · as of 2025-04-01].
- Failed strategic transactions — Several prior transactions (reverse merger, license, program sale) are not expected to move forward [sec_mda · as of 2025-08-14].
- Very low revenue — Total revenue was only $0.1M as of 2026-06-30, indicating minimal commercial activity [sec].
What to watch
- Ability to secure additional capital to initiate the Phase 3 clinical trial for Adrulipase [sec · filed 2026-07-31].
- Progress in the Grid AI energy optimization business, including any commercial contracts or partnerships [sec_mda · as of 2026-09-18].
- Cash runway and any further private placements or financing rounds [sec · filed 2026-07-31].
- Regulatory developments for Adrulipase, particularly any FDA feedback or trial design updates [sec · filed 2026-09-18].
Sources: SEC filings · SEC MD&A · Generated September 25, 2026 · How we verify sources →
Run GridAI Technologies Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GridAI Technologies Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 21, 2026- % of float
- 1.4%
- Days to cover
- 0.6
- Shares short
- 58,762
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GRDX short interestGovernance
Frequently asked questions
What is the AI investment thesis for GridAI Technologies Corp.?
GridAI Technologies Corp. (GRDX) is a post-acquisition entity combining AI-driven energy optimization technology with legacy biopharmaceutical development, primarily focused on the Adrulipase program for exocrine pancreatic insufficiency.
What is GridAI Technologies Corp.'s lead drug candidate?
GridAI Technologies Corp.'s most advanced tracked candidate is adrulipase (Phase 2) for Exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP).
Who is the CEO of GridAI Technologies Corp.?
Mr. Jason David Sawyer is the chief executive officer of GridAI Technologies Corp. (GRDX).
Where is GridAI Technologies Corp. headquartered?
GridAI Technologies Corp. (GRDX) is headquartered in Edinburgh, United Kingdom.
What therapeutic areas does GridAI Technologies Corp. focus on?
GridAI Technologies Corp. develops therapies across Oncology, Rare Disease, Respiratory, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.